Efficacy of high-dose chemotherapy combined with hematopoietic stem cell transplantation in advanced neuroblastoma

1

High-dose chemotherapy with hematopoietic stem cell transplantation (HDC+HSCT) showed higher overall response rates than high-dose chemotherapy alone in pediatric neuroblastoma.
2

The median overall survival was significantly longer in the HDC+HSCT group at 34.7 months compared to 26.1 months for the HDC group.
3

Event-free survival did not differ significantly between the HDC+HSCT and HDC groups, with medians of 21.9 and 19.9 months, respectively.
4

Severe treatment-related toxicities, including bacterial infections and mucositis, were more frequent in the HDC+HSCT group.
5

The study highlights the need for intensive supportive care in patients receiving HDC+HSCT due to increased severe toxicities.

1